ADG126 bets that masked anti-CTLA-4 can unlock MSS CRC; Phase 2 dose-optimization results will determine whether a Phase 3 registration trial is warranted

Bull

A positive outcome would show a clearly differentiated dose regimen with maintained or improved ORR (building on the 40% signal seen at 15 mg/kg in Phase 1b/2), acceptable tolerability, and durable responses — giving Adagene and regulators sufficient confidence to advance to a Phase 3 registration trial in MSS CRC without liver metastases, validating the SAFEbody masked anti-CTLA-4 approach as a genuine breakthrough in an immunotherapy-resistant tumor type.

Bear

The most likely failure modes are insufficient separation between dose arms to guide Phase 3 design, ORR that fails to hold up in a larger randomized cohort versus the small single-arm signals, or an emergent toxicity profile at higher doses that narrows the therapeutic window — any of these outcomes would stall or terminate the Phase 3 decision and undermine the core thesis that masked CTLA-4 blockade can unlock MSS CRC.